HG-81 NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION

Similar Items

• Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation
  od: Hou, Yafei, i dr.
  Izdano: (2015)
• IMPS-30 NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION
  od: Hou, Yafei, i dr.
  Izdano: (2015)
• IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN – CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY
  od: Chheda, Zinal, i dr.
  Izdano: (2017)
• Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
  od: Chheda, Zinal S., i dr.
  Izdano: (2018)
• OS09.4 Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of H3.3.K27M-specific T-cell receptor for T-cell therapy in gliomas
  od: Chheda, Z., i dr.
  Izdano: (2017)